Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol

    NEW YORK, May 1 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
 (NYSE:   FRX) announced today that its licensing partner Mylan Laboratories
 (NYSE:   MYL) submitted a response to the approvable letter issued by the
 United States Food and Drug Administration (FDA) for the compound
 nebivolol, a selective beta 1- blocker with vasodilating properties
 currently under U.S. regulatory review for the treatment of hypertension.
 Upon acceptance of this response, Forest anticipates the FDA will complete
 its review of nebivolol's new drug application within six months.
     (Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
     "We believe the supplemental data will provide the FDA with the
 information they have requested. Nebivolol has already received an
 approvable letter and we are confident that it should soon be approved. We
 expect that nebivolol will provide an important new option for physicians
 in the management of hypertension," said Howard Solomon, Chairman and Chief
 Executive Officer, Forest Laboratories. "We are excited about the
 opportunity to market nebivolol and look forward to a long-term
 collaboration with Mylan."
     Forest licensed nebivolol from Mylan Laboratories in January 2006 and
 has responsibility for all sales and marketing as well as the current and
 future development programs. Mylan has retained an option to co-promote the
 product in the future.(1)
     "In partnership with Forest Laboratories, we have secured the data
 required by the FDA in the approvable letter for nebivolol," said Robert J.
 Coury, Vice Chairman and Chief Executive Officer of Mylan Laboratories. "We
 continue to be committed to providing the necessary support for nebivolol
 to gain approval in the U.S."
     Nebivolol is a selective beta 1-adrenergic (cardioselective) receptor
 antagonist with vasodilating properties(2) and is already approved and
 successfully marketed for the treatment of hypertension in more than 50
 countries outside of North America.(3)
     About Forest Laboratories and Its Products
     Forest Laboratories is a US-based pharmaceutical company dedicated to
 identifying, developing, and delivering products that make a positive
 difference in peoples' lives. Forest Laboratories' growing product line
 includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults
 for the initial and maintenance treatment of major depressive disorder and
 generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl D-
 aspartate (NMDA)-receptor antagonist indicated for the treatment of
 moderate to severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil),
 an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil-
 hydrochlorothiazide), an angiotensin receptor blocker and diuretic
 combination product, each indicated for the treatment of hypertension; and
 Campral(R)* (acamprosate calcium), indicated in combination with
 psychosocial support for the maintenance of abstinence from alcohol in
 patients with alcohol dependence who are abstinent at treatment initiation.
     * Benicar is a registered trademark of Daiichi Sankyo, Inc., and
 Campral is a registered trademark of Merck Sante s.a.s., subsidiary of
 Merck KGaA, Darmstadt, Germany.
     About Mylan Laboratories
     Mylan Laboratories Inc. is a leading pharmaceutical company with three
 principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc.
 and UDL Laboratories Inc., and a controlling interest in Matrix
 Laboratories Limited, India. Mylan develops, licenses, manufactures,
 markets and distributes an extensive line of generic and proprietary
 products.
     Except for the historical information contained herein, this release
 contains "forward-looking statements" within the meaning of the Private
 Securities Litigation Reform Act of 1995. These statements involve a number
 of risks and uncertainties, including the difficulty of predicting FDA
 approvals, the acceptance and demand for new pharmaceutical products, the
 impact of competitive products and pricing, the timely development and
 launch of new products, and the risk factors listed from time to time in
 the Forest Laboratories' SEC reports, including the Company's Annual Report
 on Form 10-K for the fiscal year ended March 31, 2006 and on Form 10-Q for
 the periods ended June 30, 2006, September 30, 2006 and December 31, 2006.
     (1) Mylan Laboratories and Forest Laboratories joint press release,
 January 11, 2006: "Mylan Laboratories and Forest Laboratories Announce
 Nebivolol Licensing Agreement."
     (2) Tzemos, N. "Nebivolol Reverses Endothelial Dysfunction in Essential
 Hypertension: A Randomized, Double-Blind, Crossover Study." Circ. 2001;
 104:511-514.
     (3) Mylan Press Release, June 1, 2005: "Mylan Laboratories Receives
 Approvable Letter For Its Next Generation Beta-Blocker Nebivolol."
 
 

SOURCE Forest Laboratories, Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.